$348 Million is the total value of 5AM Venture Management, LLC's 26 reported holdings in Q3 2023. The portfolio turnover from Q2 2023 to Q3 2023 was 8.3% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| Sell | ENLIVEN THERAPEUTICS INC | $70,498,919 | -40.4% | 5,160,975 | -11.0% | 20.28% | -31.2% | |
| ENTRADA THERAPEUTICS INC | $69,652,388 | +4.4% | 4,408,379 | 0.0% | 20.04% | +20.5% | ||
| Sell | DISC MEDICINE INC | $20,598,005 | -5.0% | 438,442 | -10.2% | 5.93% | +9.7% | |
| New | DIANTHUS THERAPEUTICS INC | $20,125,849 | – | 1,472,264 | +100.0% | 5.79% | – | |
| Sell | MOONLAKE IMMUNOTHERAPEUTICSclass a ord | $17,852,970 | -2.1% | 313,210 | -12.4% | 5.14% | +13.1% | |
| CRNX | Sell | CRINETICS PHARMACEUTICALS IN | $13,748,386 | -11.5% | 462,286 | -46.4% | 3.96% | +2.2% |
| VOR | VOR BIOPHARMA INC | $13,486,853 | -31.4% | 6,361,723 | 0.0% | 3.88% | -20.7% | |
| PHVS | PHARVARIS N V | $12,263,212 | +37.8% | 587,600 | 0.0% | 3.53% | +59.3% | |
| RALLYBIO CORP | $12,235,540 | -40.5% | 3,630,724 | 0.0% | 3.52% | -31.2% | ||
| ZNTL | ZENTALIS PHARMACEUTICALS INC | $9,829,400 | -28.9% | 490,000 | 0.0% | 2.83% | -17.9% | |
| SCPH | SCPHARMACEUTICALS INC | $8,548,607 | -30.1% | 1,200,647 | 0.0% | 2.46% | -19.3% | |
| CLDX | CELLDEX THERAPEUTICS INC NEW | $8,538,630 | -18.9% | 310,270 | 0.0% | 2.46% | -6.3% | |
| MRTX | MIRATI THERAPEUTICS INC | $8,385,300 | +20.6% | 192,500 | 0.0% | 2.41% | +39.2% | |
| COGT | COGENT BIOSCIENCES INC | $7,706,790 | -17.7% | 790,440 | 0.0% | 2.22% | -4.8% | |
| VKTX | VIKING THERAPEUTICS INC | $6,475,950 | -31.7% | 585,000 | 0.0% | 1.86% | -21.1% | |
| ANAB | ANAPTYSBIO INC | $6,424,885 | -11.7% | 357,733 | 0.0% | 1.85% | +2.0% | |
| VRDN | Buy | VIRIDIAN THERAPEUTICS INC | $6,289,400 | -5.6% | 410,000 | +46.4% | 1.81% | +9.1% |
| ARVN | ARVINAS INC | $6,284,800 | -20.9% | 320,000 | 0.0% | 1.81% | -8.6% | |
| New | TYRA BIOSCIENCES INC | $5,665,667 | – | 411,450 | +100.0% | 1.63% | – | |
| SPRB | SPRUCE BIOSCIENCES INC | $5,342,640 | +5.1% | 2,364,000 | 0.0% | 1.54% | +21.4% | |
| FIXX | HOMOLOGY MEDICINES INC | $5,307,025 | +32.2% | 4,535,919 | 0.0% | 1.53% | +52.7% | |
| RNA | AVIDITY BIOSCIENCES INC | $4,246,241 | -42.5% | 665,555 | 0.0% | 1.22% | -33.6% | |
| GHRS | Buy | GH RESEARCH PLCordinary shares | $4,064,260 | +125.3% | 404,404 | +166.0% | 1.17% | +160.4% |
| MRSN | MERSANA THERAPEUTICS INC | $1,657,350 | -61.4% | 1,305,000 | 0.0% | 0.48% | -55.4% | |
| IMPL | IMPEL PHARMACEUTICALS INC | $1,240,460 | -66.1% | 2,884,791 | 0.0% | 0.36% | -60.9% | |
| CDTX | CIDARA THERAPEUTICS INC | $1,068,936 | -16.6% | 1,134,511 | 0.0% | 0.31% | -3.4% |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2023-11-14
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| HOMOLOGY MEDICINES INC | 16 | Q3 2023 | 26.6% |
| ARVINAS INC | 16 | Q3 2023 | 14.3% |
| Crinetics Pharmaceuticals, Inc. | 16 | Q3 2023 | 12.8% |
| SCPHARMACEUTICALS INC | 16 | Q3 2023 | 7.5% |
| CIDARA THERAPEUTICS INC | 16 | Q3 2023 | 1.7% |
| IDEAYA BIOSCIENCES INC | 14 | Q1 2023 | 11.4% |
| VOR BIOPHARMA INC | 11 | Q3 2023 | 51.9% |
| CABALETTA BIO INC | 11 | Q2 2022 | 14.2% |
| AKOUOS INC | 10 | Q3 2022 | 27.7% |
| IMPEL PHARMACEUTICALS INC | 10 | Q3 2023 | 7.1% |
View 5AM Venture Management, LLC's complete holdings history.
Latest filings
| Type | Filed |
|---|---|
| 13F-HR | 2024-02-14 |
| 13F-HR | 2023-11-14 |
| 13F-HR | 2023-08-14 |
| 13F-HR | 2023-05-15 |
| 13F-HR | 2023-02-14 |
| 13F-HR | 2022-11-14 |
| 13F-HR | 2022-08-15 |
| 13F-HR | 2022-05-16 |
| 13F-HR | 2022-02-03 |
| 13F-HR | 2021-11-15 |
View 5AM Venture Management, LLC's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.